Profile
| Role | Chief Financial Officer |
|---|---|
| Notability | 20/100 |
Board memberships
- Bicara Therapeutics Inc.
Updated Jul 16, 2026
Hyep Ivan has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $2.38M.
| Role | Chief Financial Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-10 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 830 | $30.31 | $25K |
| 2026-07-10 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 4.4K | $29.82 | $132K |
| 2026-07-10 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 22.8K | $28.60 | $651K |
| 2026-07-10 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 12.5K | $3.79 | $47K |
| 2026-05-26 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 9.2K | $20.42 | $188K |
| 2026-05-26 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 9.2K | $3.79 | $35K |
| 2026-04-22 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 9.2K | $23.00 | $212K |
| 2026-04-22 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 9.2K | $3.79 | $35K |
| 2026-03-24 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 9.2K | $18.52 | $170K |
| 2026-03-24 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 9.2K | $3.79 | $35K |
| 2026-03-06 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 3.0K | $18.25 | $54K |
| 2026-03-06 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 3.0K | $3.79 | $11K |
| 2026-03-06 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 13.6K | $18.22 | $247K |
| 2026-03-06 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 6.2K | $3.79 | $24K |
| 2026-03-06 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 7.3K | $3.79 | $28K |
| 2026-01-26 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale [10b5-1] | 1.9K | $18.15 | $34K |
| 2026-01-26 | BCAX | Bicara Therapeutics Inc. | M — Option exercise [10b5-1] | 1.9K | $3.79 | $7K |
| 2025-10-09 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 6.4K | $18.23 | $117K |
| 2025-10-09 | BCAX | Bicara Therapeutics Inc. | M — Option exercise | 6.4K | $3.79 | $24K |
| 2025-10-06 | BCAX | Bicara Therapeutics Inc. | S — Open-market sale | 5.6K | $18.21 | $102K |
Hyep Ivan is a corporate insider — currently tracked as Chief Financial Officer of Bicara Therapeutics Inc. (BCAX). InsiderAlpha tracks every SEC Form 4 filing in real time.
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($2.38M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hyep Ivan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.